Citations

Clear

9383 citation(s) found for "Thomas, PS".

Eigen-Entropy based Time Series Signatures to Support Multivariate Time Series Classification
Patharkar, Abhidnya , Forzani, Erica , Thomas, Leslie F., Gades, Naomi M. , Huang, Jiajing , Wu, Teresa , Lind, Mary Laura

Mayo Clinic

No container title available | April 15, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4156209/v1 Get It

Abstract Most current algorithms for multivariate time series classification tend to overlook the correlations between time series of different variables. In this research, we propose a framework that leverages Eigen-entropy along with a cumulative moving window to derive time series signatures to support the classification task. These signatures are enumerations of correlations among different time series considering the temporal nature of the dataset. To manage dataset's dynamic nature, we employ preprocessing with dense multi scale entropy. Consequently, the proposed framework, Eigen-entropy-based Time Series Signatures, captures correlations among multivariate time series without losing its temporal and dynamic aspects. The efficacy of our algorithm is assessed using six binary datasets sourced from the University of East Anglia (UEA), in addition to a publicly available sepsis dataset and an institutional sepsis dataset from the Mayo Clinic. We employ recall as a metric for evaluation against the baseline algorithm, Dependent Dynamic Time Warping with 1 Nearest Neighbor. Our algorithm outperforms the baseline algorithm for UEA datasets in terms of recall with an average value of 10% across all datasets, and by 38% for an institutional sepsis dataset. For the public sepsis dataset, the performance of our algorithm is comparable to the baseline algorithm.
Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial
So, Helen , Fervenza, Fernando C. , Cattran, Daniel C., Barbour, Sean J. , Investigators, MENTOR Study, Cattran, D C, Appel, Gerald B., Gipson, D, Erickson, Stephen B., Radhakrishnan, Jay, Bomback, A.S., Hogan, Jonathan, Arora, Neha , Nargund, Preeti, Alvarado, Anthony, Hebert, Lee A., Aslam, Nabeel , Porter, Ivan E. , Gipson, Patrick E., Plattner, Brandon L. , Gipson, D, Mariani, Laura , Garg, Pranay, Jefferson, J. Ashley , Nelson, Peter J. , Yarlagadda, Sri G. , Simon, James F. , Gebreselassie, Surafel , Blumenthal, Stanley A., Thomas, L, Cohen, Irvin M., Keddis, Mira T. , Sussman, Andrew L. , Thajudeen, Bijin , Fülöp, Tibor , Craici, Iasmina , Wagner, Steven J., DREISBACH, A, Monga, D., Green, D, Nayer, Ali, Thomas, D. B., Cattran, D C, Reich, Heather N. , Barbour, S. Lee , Philibert, D., Mac‐Way, Fabrice , Desmeules, Simon, Ankawi, Ghada , Sethi, Sanjeev , Ávila-Casado, Carmen , Beanlands, Heather , Fervenza, Fernando C , Kadatz, Matthew , Klarenbach, Scott W , Investigators, MENTOR Study, Cattran, D C, Gipson, D, Kretzler, Matthias , Rovin, Brad H. , Lieske, John C. , Leung, Nelson , Canetta, Pietro A. , Ahn, W, Lafayette, Richard , Arora, N, Parikh, Samir M. , Plattner, B, Gipson, D, Rao, P, Sedor, John R. , O'Toole, J, McCarthy, E, Jain, Namrata Gargee , Rizk, D, Blumenthal, S, Beara‐Lasić, Lada , Zhdanova, Olga A. , Thomas, L, Sussman, A, Juncos, Luis A. , Fulop, T, Monga, D, Mattiazzi, Adela D. , Thomas, D, Barisoni, Laura , Li, T, Vijayan, Anitha , Cattran, D C, Hladunewich, Michelle , Barbour, S, Levin, Adeera , Philibert, D

Mayo Clinic

Nephrology Dialysis Transplantation | April 13, 2024 | Volume: 39 | Issue: 12 | Pages: 2058-2066

10.1093/ndt/gfae084 | PMID 38621719 Get It

ABSTRACT Background and hypothesis The MENTOR trial (MEmbranous Nephropathy Trial Of Rituximab) showed that rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria and was superior in maintaining proteinuria remission. However, the cost of rituximab may prohibit first-line use for some patients and health-care payers. Methods A Markov model was used to determine the incremental cost-effectiveness ratio (ICER) of rituximab compared with cyclosporine for the treatment membranous nephropathy from the perspective of a health-care payer with a lifetime time horizon. The model was informed by data from the MENTOR trial where possible; additional parameters including cost and utility inputs were obtained from the literature. Sensitivity analyses were performed to evaluate the impact of reduced-cost biosimilar rituximab. Results Rituximab for the treatment of membranous nephropathy was cost effective (assuming a willingness-to-pay threshold of $50 000 per quality-adjusted life year (QALY) gained; in $US 2021) compared with cyclosporine, with an ICER of $8373/QALY over a lifetime time horizon. The incremental cost of rituximab therapy was $28 007 with an additional 3.34 QALYs compared with cyclosporine. Lower cost of rituximab biosimilars resulted in a more favorable ICER, and in some cases resulted in rituximab being dominant (lower cost and great benefit) compared to cyclosporine. Conclusions Despite the greater cost of rituximab, it may be a cost-effective option for the treatment of membranous nephropathy when compared with cyclosporine. The cost-effectiveness of rituximab is further improved with the use of less expensive biosimilars.
Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup
Bellomo, Rinaldo , Ankawi, Ghada , Baldwin, Ian , Bottari, Gabriella , Clark, William R. , Rosa, Silvia De , Fuhrman, Dana Y. , Goldstein, Stuart L. , Gómez, Hernando , Joannidis, Michael , Lorenzin, Anna , Murugan, Ragi, Premužić, Vedran , Prowle, John R. , Rimmelé, Thomas , Rosner, Mitch, Schneider, Antoine , Zarbock, Alexander , Bagshaw, Sean M. , Basu, Rajit K. , Cantaluppi, Vincenzo , Forni, Lui G. , Husain‐Syed, Faeq , Kashani, Kianoush , Mehta, Ravindra L. , Murray, Patrick T. , Ostermann, Marlies , Pannu, Neesh , Reis, Thiago , Ronco, Claudio , Rosner, Mitchell H. , See, Emily , Soranno, Danielle E. , Villa, Gianluca , Whaley‐Connell, Adam T.

Mayo Clinic

Nephrology Dialysis Transplantation | April 13, 2024 | Volume: 39 | Issue: 12 | Pages: 1945-1964

10.1093/ndt/gfae089 | PMID 38621759 Get It

ABSTRACT Adsorption-based extracorporeal therapies have been subject to technical developments and clinical application for close to five decades. More recently, new technological developments in membrane and sorbent manipulation have made it possible to deliver more biocompatible extracorporeal adsorption therapies to patients with a variety of conditions. There are several key rationales based on physicochemical principles and clinical considerations that justify the application and investigation of such therapies as evidenced by multiple ex vivo, experimental and clinical observations. Accordingly, unspecific adsorptive extracorporeal therapies have now been applied to the treatment of a wide array of conditions from poisoning to drug overdoses, to inflammatory states and sepsis, and acute or chronic liver and kidney failure. In response to the rapidly expanding knowledge base and increased clinical evidence, we convened an Acute Disease Quality Initiative consensus conference dedicated to such treatment. The data show that hemoadsorption has clinically acceptable short-term biocompatibility and safety, technical feasibility and experimental demonstration of specified target molecule removal. Pilot studies demonstrate potentially beneficial effects on physiology and larger studies of endotoxin-based hemoadsorption have identified possible target phenotypes for larger randomized controlled trials. Moreover, in a variety of endogenous and exogenous intoxications, removal of target molecules has been confirmed in vivo. However, some studies have raised concerns about harm, or failed to deliver benefits. Thus, despite many achievements, modern hemoadsorption remains a novel and experimental intervention with limited data, and a large research agenda.
Outcome of lung transplantation in patients with pulmonary alveolar microlithiasis in the era of COVID-19 infection
Raavi, Lekhya , Garg, Pankaj , Alomari, Mohammad , Celik, Nafiye Busra , Makey, Ian A. , Thomas, Mathew , Nassar, Aziza , Sareyyüpoğlu, Başar , Jacob, Samuel , Ahmed, Magdy M. El‐Sayed , Thomas, Mathew , Celik, Nafiye B, Pham, Si M. , Nassar, Aziza , Thomas, Mathew , Garg, Pankaj

Mayo Clinic

Journal of Surgical Case Reports | April 11, 2024 | Volume: 2024 | Issue: 4 | Pages: No page available

10.1093/jscr/rjae211 | PMID 38605700 Get It

Abstract Lung transplant recipients are at higher risk of developing COVID-19 infection compared to other solid organ transplants. The risk further increases in the unvaccinated patients. We present a case of a 43-year-old male who underwent bilateral sequential lung transplantation for pulmonary alveolar microlithiasis (PAM) and had an uneventful recovery. However, two years post-transplantation, the patient developed chronic lung allograft dysfunction (CLAD) with bronchiolitis obliterans syndrome and two episodes of COVID-19 infection. During the second episode of COVID-19 infection, the patient developed sepsis and multi-organ dysfunction ultimately resulting in death. Our case report highlights the increased susceptibility of PAM patients’ post-lung transplant to COVID-19 infection. Continuous follow-up of PAM patients’ post-lung transplantation is necessary to prevent unfavorable outcomes.
Tumor-Extrinsic Axl Expression Shapes an Inflammatory Microenvironment Independent of Tumor Cell Promoting Axl Signaling in Hepatocellular Carcinoma
Breitenecker, Kristina , Heiden, Denise, Demmer, Tobias, Weber, Gerhard, Primorac, Ana-Maria, Hedrich, Viola , Ortmayr, Gregor , Gruenberger, Thomas , Herndler‐Brandstetter, Dietmar , Barozzi, Iros , Mikulits, Wolfgang , Herndler-Brandstetter, Dietmar , Barozzi, Iros , Mikulits, Wolfgang , Gruenberger, Thomas , Weber, Gerhard, Starlinger, Patrick

Mayo Clinic

International Journal of Molecular Sciences | April 11, 2024 | Volume: 25 | Issue: 8 | Pages: 4202

10.3390/ijms25084202 | PMID 38673795 Get It

The activation of the receptor tyrosine kinase Axl by Gas6 is a major driver of tumorigenesis. Despite recent insights, tumor cell-intrinsic and -extrinsic Axl functions are poorly understood in hepatocellular carcinoma (HCC). Thus, we analyzed the cell-specific aspects of Axl in liver cancer cells and in the tumor microenvironment. We show that tumor-intrinsic Axl expression decreased the survival of mice and elevated the number of pulmonary metastases in a model of resection-based tumor recurrence. Axl expression increased the invasion of hepatospheres by the activation of Akt signaling and a partial epithelial-to-mesenchymal transition (EMT). However, the liver tumor burden of Axl+/+ mice induced by diethylnitrosamine plus carbon tetrachloride was reduced compared to systemic Axl−/− mice. Tumors of Axl+/+ mice were highly infiltrated with cytotoxic cells, suggesting a key immune-modulatory role of Axl. Interestingly, hepatocyte-specific Axl deficiency did not alter T cell infiltration, indicating that these changes are independent of tumor cell-intrinsic Axl. In this context, we observed an upregulation of multiple chemokines in Axl+/+ compared to Axl−/− tumors, correlating with HCC patient data. In line with this, Axl is associated with a cytotoxic immune signature in HCC patients. Together these data show that tumor-intrinsic Axl expression fosters progression, while tumor-extrinsic Axl expression shapes an inflammatory microenvironment.
Transoral Robotic Surgery for Eagle Syndrome: A Systematic Review
Keirns, Darby , Entezami, Payam , Ware, Erin , Nagel, Thomas H. , Asarkar, Ameya A , Chang, Brent A.

Mayo Clinic

Ear, Nose & Throat Journal | April 11, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/01455613241246587 | PMID 38600743 Get It

Objectives: Transoral robotic surgery (TORS) is gaining popularity and has been introduced for the treatment of Eagle syndrome. This review aims to evaluate the safety and efficacy of TORS for the treatment of Eagle syndrome. Methods: A systematic review of the English language literature using multiple databases was completed for studies describing TORS for Eagle syndrome. The quality of studies and risk of bias were evaluated using the MINORS scoring system. Results: Out of 1495 articles screened, 4 studies met criteria for inclusion in the final analysis. Across all studies, there was a 100% surgical success rate. In total, every patient had some level of symptom improvement with 84% of patients having complete symptom improvement and 16% having partial improvement. Reported estimated blood loss averaged 12.5 mL. A total of 94.7% of patients had no surgical complications and no cases were complicated by postoperative bleeding. Operative time averaged 65 minutes. The average length of stay was 2.1 days. A total of 92% of patients resumed their diet on postoperative day 1, with the remainder resuming on postoperative day 2. MINORS criteria scoring suggested moderate risk of bias in all studies. Conclusion: Based on limited quality evidence, this review suggests that TORS is a safe and effective surgical approach in the treatment of Eagle syndrome with low complication rates. Further large-scale prospective studies are warranted.
Conjugal Synucleinopathies: A Clinicopathologic Study
Adler, Charles H. , Halverson, Matthew , Shill, Holly A. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Caviness, John N., Belden, Christine M. , Long, Kathy E., Beach, Thomas G. , Driver-Dunckley, Erika, Beach, Thomas G , Adler, C H , Zhang, Nan , Driver‐Dunckley, Erika , Atri, Alireza , Serrano, Geidy E. , Shprecher, David , Sabbagh, Marwan Noel

Mayo Clinic

Movement Disorders | April 10, 2024 | Volume: 39 | Issue: 7 | Pages: 1212-1217

10.1002/mds.29783 | PMID 38597193 Get It

AbstractBackgroundWhile preclinical studies have shown that alpha‐synuclein can spread through cell‐to‐cell transmission whether it can be transmitted between humans is unknown.ObjectivesThe aim was to assess the presence of a synucleinopathy in autopsied conjugal couples.MethodsNeuropathological findings in conjugal couples were categorized as Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease with Lewy bodies (ADLB), incidental Lewy body disease (ILBD), or no Lewy bodies.ResultsNinety conjugal couples were included; the mean age of death was 88.3 years; 32 couples had no Lewy bodies; 42 couples had 1 spouse with a synucleinopathy: 10 PD, 3 DLB, 13 ADLB, and 16 ILBD; 16 couples had both spouses with a synucleinopathy: in 4 couples both spouses had PD, 1 couple had PD and DLB, 4 couples had PD and ADLB, 2 couples had PD and ILBD, 1 couple had DLB and ADLB, in 3 couples both had ADLB, and 1 couple had ADLB and ILBD. No couples had both spouses with ILBD.ConclusionsThis large series of 90 autopsied conjugal couples found 16 conjugal couples with synucleinopathies, suggesting transmission of synucleinopathy between spouses is unlikely. © 2024 International Parkinson and Movement Disorder Society.
Frameless, Virtual Cone Linac-based Stereotactic Radiosurgery for Essential & Parkinsonian Tremor: A Phase I/II Prospective Clinical Trial (S35.001)
Thomas, Evan , Walker, Harrison C. , Middlebrooks, Erik H. , McCullough, Benjamin, Stover, Natividad , Guthrie, Barton L. , Popple, Richard A. , Fiveash, John B. , Bredel, Markus , Middlebrooks, Erik H , Sung, Victor , Standaert, David G. , Bentley, J. Nicole , Holland, Marshall T.

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000208138 Get It

Is There an Increased Risk of Developing Dementia in Patients with Essential Tremor? (S35.002)
Sherfinski, Emma, Mangipudi, Kartik, Shill, Holly A. , Belden, Christine M. , Beach, Thomas G. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Zhang, Nan , Adler, Charles H. , Atri, Alireza , Driver‐Dunckley, Erika

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205524 Get It

Transcutaneous Spinal Cord Stimulation (ARC-EX Therapy) Is Safe and Effective at Improving Upper Extremity Function Following Spinal Cord Injury (P7-11.001)
Tefertiller, Candace , Morse, Leslie R. , Purcell, Mariel , Murray, Lynda M. , Wecht, Jill M. , Rieger, Markus, Pradarelli, Jared , Suggitt, Jenny , Turner, Amanda, Gelenitis, Kristen , Trumbower, Randy D. , Nes, Ilse J. W. van , Kalsi‐Ryan, Sukhvinder , Janssen, Thomas W. J. , Krassioukov, Andrei V. , Zhao, Kristin D. , Guest, James D. , Marino, Ralph J. , D’Amico, Jessica M. , Moritz, Chet T. , Field-Fote, Edelle Carmen

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205724 Get It